A Phase 1 interventional study of JNJ-42847922 5 mg and JNJ-42847922 10 mg in Healthy, sponsored by Janssen-Cilag International NV. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-01-24.
Sponsored by Janssen-Cilag International NV (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to investigate the safety, tolerability, pharmacokinetic (the study of the way a drug enters and leaves the blood and tissues over time), dose-proportionality, accumulation, urinary excretion, pharmacodynamics (the study of how drugs act on the body) and sedative effects of JNJ-42847922 in healthy male and female participants.
This is a Phase 1, double blind (a medical research study in which neither the researchers nor the participants know what treatment the participants is receiving), randomized (study drug assigned by chance), placebo controlled, multiple ascending dose study. The study will consist of 3 parts: a Screening period (Days -21 to -2), a Double-blind treatment period (Day -1 to Day 11), and a Follow-up period (within 7 to 14 days after last dose administration). In double blind treatment period, participants will be randomly assigned to 5, 10, 20, and 40 milligram (mg) or placebo. Number of participants with any clinically relevant changes (adverse events [AEs], laboratory results,electrocardiogram [ECG], Vital signs, Physical and neurological, sedation \& concentration) and columbia suicide severity rating (CSSR) scale will be evaluated as primary outcome measure. Participants' safety will be monitored throughout the study.
Janssen-Cilag International NV is the lead sponsor of 67 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be receive either 5 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
Drug: JNJ-42847922 5 mg · Drug: Placebo
Participants will be receive either 10 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
Drug: JNJ-42847922 10 mg · Drug: Placebo
Participants will be receive either 20 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
Drug: JNJ-42847922 20 mg · Drug: Placebo
Participants will be receive either 40mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
Drug: JNJ-42847922 40 mg · Drug: Placebo
Participants will receive 5 mg of JNJ-42847922, from Day 1 up to Day 10.
Participants will receive 10 mg of JNJ-42847922, from Day 1 up to Day 10.
Participants will receive 20 mg of JNJ-42847922, from Day 1 up to Day 10.
Participants will receive 40 mg of JNJ-42847922, from Day 1 up to Day 10 .
Participants will receive matching placebo from Day 1 up to Day 10.
Supine and Standing Systolic and Diastolic Blood Pressure (BP)
BP is the pressure of the blood within the arteries. It is produced primarily by the contraction of the heart muscle. BP measurement is recorded by 2 numbers: systolic BP (SBP, BP when heart is contracting; it is the maximum arterial pressure during contraction of left ventricle) and diastolic BP (DBP, BP when heart is relaxing; it is the minimum arterial pressure during relaxation and dilation of ventricles).
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Supine and Standing Heart Rate
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Tympanic Temperature
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
12 Lead Electrocardiogram (ECG): RR, QRS, PR, QT, QTcB, QTcF Interval
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Columbia Suicide Severity Rating Scale (C-SSRS)
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Number of Participants with Adverse Events
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Number of Participants With Change From Baseline in Laboratory Tests Results
Laboratory values included Hematology, clinical chemistry and urinalysis.
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Physical and Neurological Examination
Physical and neurological examination will be performed.
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Maximum Plasma Concentration (C[max])
The C(max) is the maximum plasma concentration which will be observed at the defined time points.
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Time to Reach the Maximum Plasma Concentration (T[max])
The T\[max\] is time to reach the observed maximum plasma concentration.
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Time to Reach Last Quantifiable Plasma Concentration (T[last])
The T\[last\] is time to reach the observed maximum plasma concentration.
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Area Under the Plasma Concentration-Time Curve From Time Zero to hour 24 Time (AUC [0-24])
AUC (0-24) is the area under the plasma concentration-time curve from time 0 to 24 hours post-dose.
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-last])
AUC (last) is the area under the plasma concentration-time curve from time zero time of the last quantifiable concentration C(last), and C(last) is the last observed quantifiable concentration.
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity])
AUC (infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z), wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time; and C(last) is the last observed quantifiable concentration; and lambda(z) is elimination rate constant.
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Average Plasma Concentration at Steady-State (C[avg])
C(avg) is the average plasma concentration at steady state, calculated as AUC 0-24 divided by 24
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Trough Plasma Concentration (C[trough])
Trough plasma concentration is the plasma concentration before dosing or at the end of the dosing interval of any dose other than the first dose.
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Total Clearance (CL/F)
CL/F is the total clearance of drug after extravascular administration, uncorrected for absolute bioavailability. It is calculated as Dose divided by AUC.
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Volume of Distribution (Vd/F)
Vd/F is the volume of distribution after extravascular administration, uncorrected for absolute bioavailability.
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Elimination Half-life Period (t1/2)
Elimination half-life associated with the terminal slope (lambda\[z\]) of the semi logarithmic drug concentration-time curve, calculated as 0.693/lambda (z).
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Terminal slope (Lambda [z])
Terminal slope is defined by first-order rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve.
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Mean Residence Time (MRT)
MRT is the mean residence time calculated as area under the first moment curve at infinity (AUMC\[0-∞\]) divided by AUC\[0-∞\].
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Amount of Drug Excreted in Urine (Ae)
Ae is the amount of urine excreted in urine. It is calculated by multiplying the urinary volume with the urinary concentration.
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Amount of Drug Excreted into Urine During the 24-hour Dosing Interval (Ae[0-24])
Ae(0-24h) is the amount of drug excreted into urine during the 24-hour dosing interval.
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Percentage of Drug Excreted in Urine (Ae%dose)
Ae%dose is the percentage of drug excreted into the urine calculated as (Ae divided by dose)∗100.
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Renal Clearance (CL[R])
CL(R) is the renal clearance of the drug, calculated as Ae/AUC\[0-infinity\] on Day 1 or Ae(0-24)/AUC(0-24) on Day 5 and Day 10.
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Assessment of Sedation
Sedation will be assessed using a reaction time (RT) test battery, the Critical Flicker Fusion (CFF) test and body sway.
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Bond and Lader Visual Analogue Scale (B and L VAS)
The B and L VAS includes 16 questions with VAS scales to rate subjective feelings.
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
Addiction Research Center Inventory Questionnaire (ARCI-49)
The ARCI-49 item questionnaire is developed specifically to measure subjective effects of drugs with diverse pharmacological actions.
Time frame: Baseline up to End of study (7-14 days after last dose) or Early withdrawal
The record gives a start of May 2014, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Seltorexant
Janssen-Cilag International NV →